Search results
Results from the WOW.Com Content Network
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
The first discovered c-glucoside was the drug dapagliflozin. [1] [14] [15] Dapagliflozin was the first highly selective SGLT-2-inhibitor approved by the European Medicines Agency. [16] All SGLT-2 inhibitors in clinical development are prodrugs that have to be converted to its active 'A' form for activity. [9]
This page was last edited on 2 December 2024, at 21:02 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
For premium support please call: 800-290-4726 more ways to reach us
The Affordable Care Act’s chief aim is to extend coverage to people without health insurance. One of the 2010 law’s primary means to achieve that goal is expanding Medicaid eligibility to more people near the poverty level. But a crucial court ruling in 2012 granted states the power to reject the Medicaid expansion.
Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist. [32] [33] Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. [34]
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.
Dapagliflozin/metformin was approved for use in the European Union in January 2014, [3] in the United States in February 2014, [5] [6] and in Australia in July 2014. [ 7 ] Adverse effects